Detalhe da pesquisa
1.
Breast Cancer Brain Metastases: Achilles' Heel in Breast Cancer Patients' Care.
Cancer Treat Res
; 188: 283-302, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175350
2.
Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.
Cancer Treat Res
; 188: 219-235, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175348
3.
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer.
Cancer Treat Res
; 188: 237-281, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175349
4.
Postneoadjuvant treatment for triple-negative breast cancer.
Curr Opin Oncol
; 34(6): 623-634, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35993306
5.
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Breast Cancer Res
; 23(1): 84, 2021 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380530
6.
Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?
Breast Cancer Res Treat
; 189(2): 307-315, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34263366
7.
Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
Adv Exp Med Biol
; 1168: 9-30, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31713162
8.
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
Oncology
; 94 Suppl 1: 19-28, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30036884
9.
Sorafenib: 10 years after the first pivotal trial.
Future Oncol
; 11(13): 1863-80, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26161924
10.
Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
Eur J Cancer
; 207: 114175, 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38896996
11.
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Breast
; 69: 451-468, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156650
12.
Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Cancer Treat Rev
; 109: 102436, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35870237
13.
Accelerating drug development in breast cancer: New frontiers for ER inhibition.
Cancer Treat Rev
; 109: 102432, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839531
14.
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.
Cancer Drug Resist
; 5(4): 971-980, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627895
15.
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
NPJ Breast Cancer
; 8(1): 37, 2022 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35319017
16.
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
Nat Commun
; 12(1): 6667, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34795269
17.
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Clin Cancer Res
; 27(12): 3443-3455, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785482
18.
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Future Oncol
; 11(16): 2263-6, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26260805
19.
Evaluating triptorelin as a treatment option for breast cancer.
Expert Opin Pharmacother
; 20(15): 1809-1818, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31500470
20.
Homologous recombination deficiency in triple negative breast cancer.
Breast
; 45: 15-21, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30818144